Metformin Disappoints in Two Phase 2 Lung Cancer Trials : co

Although well tolerated, metformin did not improve survival when given alongside chemoradiotherapy to patients with locally advanced non-small cell lung cancer (NSCLC).

Related Keywords

Munich , Bayern , Germany , Chukwuka Eze , Theodoros Tsakiridis , Heathd Skinner , University Hospital , Astrazeneca , Mcmaster University , University Of Pittsburgh Hillman Cancer Center , Research Directions , Juravinski Cancer Center , Pittsburgh Hillman Cancer Center , Lung Cancer , Ung Carcinoma , Ancer Lung , Lung , Cancer , Alignant Neoplasia , Arcinoma , Non Small Cell Lung Cancer , Nsclc , Diabetes Mellitus , Chemotherapy , Radiation Oncology , Clinical Research , Clinical Trials , Linical Studies , Tolerance , Biologic Therapy , Immunotherapy , Neoplasm , Tumor , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , Ituximab , U11248 , Unitinib , Nra ,